{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:28Z","timestamp":1790710948033,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Taichung Veterans General Hospital\/National Chung Hsing University Joint Research Program","award":["TCVGH-NCHU1107603"],"award-info":[{"award-number":["TCVGH-NCHU1107603"]}]},{"name":"the MOST Clinical Trial Consortium for Stroke","award":["MOST 108-2321-B-039-003-"],"award-info":[{"award-number":["MOST 108-2321-B-039-003-"]}]},{"name":"the Tseng-Lien Lin Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Contrast-induced acute kidney injury (CIAKI) is a common complication after percutaneous coronary intervention (PCI) in type 2 diabetes mellitus (T2DM). The protective role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) against CIAKI remains unclear. We aimed to evaluate the effects of SGLT2i using nationwide database analysis and experimental models. A nationwide nested case\u2013control study using Taiwan\u2019s National Health Insurance Research Database assessed the association between SGLT2i use and risk of post-PCI dialysis. Parallel in vitro experiments examined dapagliflozin in iopamidol-treated HK-2 cells, and in vivo studies tested dapagliflozin in diabetic rats exposed to iopamidol. Clinically, SGLT2i use significantly reduced the risk of post-PCI dialysis (adjusted OR 0.33, 95% CI 0.14\u20130.76; p = 0.0094). In vitro, dapagliflozin attenuated iopamidol-induced cytotoxicity and NLRP3 inflammasome activation in HK-2 cells. In diabetic rats, dapagliflozin improved renal function, reduced tubular injury, and suppressed inflammasome-driven inflammation. In conclusion, SGLT2i protect against CIAKI by mitigating tubular injury and inflammasome activation. These findings highlight their potential as a preventive strategy for CIAKI in T2DM patients undergoing PCI.<\/jats:p>","DOI":"10.3390\/ijms27041684","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T18:02:01Z","timestamp":1770660121000},"page":"1684","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SGLT2 Inhibitors Mitigate Contrast-Induced Acute Kidney Injury in Diabetes: Clinical and Experimental Evidence"],"prefix":"10.3390","volume":"27","author":[{"given":"Mu-Chi","family":"Chung","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"},{"name":"Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402204, Taiwan"},{"name":"Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402204, Taiwan"},{"name":"Division of Clinical Toxicology, Department of Medical Toxicology, Taichung Veterans General Hospital, Taichung 407219, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402204, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-3830","authenticated-orcid":false,"given":"Yu-Teng","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"},{"name":"Department of Medical Research, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jia","family":"Guo","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402202, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Jung","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Public Health, China Medical University, Taichung 406040, Taiwan"},{"name":"Department of Medical Research, China Medical University Hospital, Taichung 406040, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laing-You","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Public Health, China Medical University, Taichung 406040, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8585-4392","authenticated-orcid":false,"given":"Ming-Ju","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan"},{"name":"Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402204, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402204, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung 402306, Taiwan"},{"name":"Graduate Institute of Biomedical Sciences, School of Medicine, College of Medicine, China Medical University, Taichung 406040, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-3603","authenticated-orcid":false,"given":"Jeng-Jer","family":"Shieh","sequence":"additional","affiliation":[{"name":"Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402204, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402204, Taiwan"},{"name":"Department of Medical Research, Taichung Veterans General Hospital, Taichung 407219, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402202, Taiwan"},{"name":"Graduate Institute of Chinese Medicine and Drug Development, National Chung Hsing University, Taichung 402204, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome","volume":"12","author":"Muskiet","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Herrington","year":"2022","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e230453","DOI":"10.1001\/jamanetworkopen.2023.0453","article-title":"Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan","volume":"6","author":"Chung","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11886-019-1107-y","article-title":"Epidemiology of Diabetes Mellitus and Cardiovascular Disease","volume":"21","author":"Glovaci","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrneph.2016.196","article-title":"Understanding and preventing contrast-induced acute kidney injury","volume":"13","author":"Fahling","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Meregildo-Rodriguez, E.D., Asmat-Rubio, M.G., and Vasquez-Tirado, G.A. (2023). SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: Systematic review and meta-analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1307715"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1186\/s40001-024-02214-7","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and contrast-associated acute kidney injury in patients with type 2 diabetes undergoing angiography: A propensity-matched study","volume":"29","author":"Yang","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22937","DOI":"10.1038\/s41598-024-74233-7","article-title":"Short term sodium glucose transport protein 2 inhibitors are associated with post contrast acute kidney injury in patients with diabetes","volume":"14","author":"Zang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gene.2019.05.009","article-title":"Potential protective effects of Dapagliflozin in gentamicin induced nephrotoxicity rat model via modulation of apoptosis associated miRNAs","volume":"707","author":"Mohamed","year":"2019","journal-title":"Gene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","article-title":"Empagliflozin suppresses inflammation and protects against acute septic renal injury","volume":"29","author":"Maayah","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"F401","DOI":"10.1152\/ajprenal.00408.2004","article-title":"High ambient glucose is effect neutral on cell death and proliferation in human proximal tubular epithelial cells","volume":"289","author":"Morais","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_15","first-page":"442","article-title":"Renal failure after percutaneous coronary intervention is associated with high mortality","volume":"64","author":"Gupta","year":"2005","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_16","first-page":"409","article-title":"Acute renal failure requiring dialysis after percutaneous coronary interventions","volume":"52","author":"Gruberg","year":"2001","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106597","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13098-023-01107-9","article-title":"The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study","volume":"15","author":"Feitosa","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"111624","DOI":"10.1016\/j.biopha.2021.111624","article-title":"SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction","volume":"139","author":"Ahmed","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/atm.2019.09.03","article-title":"The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus","volume":"7","author":"Leng","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100895","DOI":"10.1016\/j.eclinm.2021.100895","article-title":"Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial","volume":"37","author":"Laursen","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"249810","DOI":"10.1155\/2014\/249810","article-title":"Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media","volume":"2014","author":"Michael","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrneph.2014.67","article-title":"Proteostasis in endoplasmic reticulum\u2014New mechanisms in kidney disease","volume":"10","author":"Inagi","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8277","DOI":"10.3892\/mmr.2017.7599","article-title":"Autophagy is activated to protect renal tubular epithelial cells against iodinated contrast media-induced cytotoxicity","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1172\/JCI96640","article-title":"Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury","volume":"128","author":"Lau","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101254","DOI":"10.1016\/j.redox.2019.101254","article-title":"PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation","volume":"26","author":"Lin","year":"2019","journal-title":"Redox Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1002\/cpz1.78","article-title":"Streptozotocin-Induced Diabetic Models in Mice and Rats","volume":"1","author":"Furman","year":"2021","journal-title":"Curr. Protoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e22078","DOI":"10.1096\/fj.202100909RR","article-title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney","volume":"36","author":"Ke","year":"2022","journal-title":"FASEB J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e20230187","DOI":"10.1590\/2175-8239-jbn-2023-0187en","article-title":"SGLT2 inhibitors and NLRP3 inflammasome: Potential target in diabetic kidney disease","volume":"46","author":"Lass","year":"2024","journal-title":"Bras. J. Nefrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/FJC.0000000000001268","article-title":"Dapagliflozin Attenuates Contrast-induced Acute Kidney Injury by Regulating the HIF-1\u03b1\/HE4\/NF-\u03baB Pathway","volume":"79","author":"Huang","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_33","first-page":"2655","article-title":"Tetramethylpyrazine alleviates acute kidney injury by inhibiting NLRP3\/HIF-1\u03b1 and apoptosis","volume":"22","author":"Sun","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/nep.13804","article-title":"Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease\u2014An Executive Summary","volume":"25","author":"Liew","year":"2020","journal-title":"Nephrology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10157-019-01750-5","article-title":"Guideline on the use of iodinated contrast media in patients with kidney disease 2018","volume":"24","author":"Isaka","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chen, Y.H., Fu, Y.C., and Wu, M.J. (2019). Does Resveratrol Play a Role in Decreasing the Inflammation Associated with Contrast Induced Nephropathy in Rat Model?. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020147"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1684\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:50:49Z","timestamp":1771577449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041684"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041684","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}